Biotech bearish stocks: Prothena Corporation (NASDAQ:PRTA), Oncomed Pharmaceuticals (NASDAQ:OMED), Enanta Pharmaceuticals (NASDAQ:ENTA), Vanda Pharmaceuticals (NASDAQ:VNDA)

Shares of Prothena Corp PLC (NASDAQ:PRTA) were the recipient of a large increase in short interest in the month of January. As of March 14th, there was short interest totaling 824,645 shares, an increase of 35.0% from the February 28th total of 610,797 shares, reports. Prothena Corporation PLC (NASDAQ:PRTA) stock performance was -13.98% in last session and finished the day at $29.60. Traded volume was 515,674.00million shares in the last session and the average volume of the stock remained 279.18K shares. Prothena Corporation PLC (NASDAQ:PRTA) insider ownership is 44.11%.

Late last year, the biopharma major inked a deal with OncoMed Pharmaceuticals Inc (NASDAQ:OMED) for the joint development and commercialization of up to six anti-cancer stem cell candidates from the latter’s biologics pipeline. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) dropped -13.44 percent to $26.22 Friday on volume of 335,657.00million shares. The intra-day range of the stock was $26.00 to $31.98. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has a market capitalization of $772.98million.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) CEO Jay Luly sold 15,000 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) stock on the open market in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $39.17, for a total transaction of $587,550.00. Enanta Pharmaceuticals Inc (NASDAQ:ENTA)’s stock on Apr 04, 2014 reported a decrease of -10.47% to the closing price of $34.47. Its fifty two weeks range is $16.18-$43.73. The total market capitalization recorded $632.99million. The overall volume in the last trading session was 532,012.00million shares. In its share capital, ENTA has 18.36million outstanding shares.

Sage Therapeutics, a Cambridge-based biopharmaceutical company, has appointed Howard H. Pien to its board of directors. Pien has been a chairman of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a CNS development company. On Friday, shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) dropped -10.03% to close the day at $15.07. Company return on investment (ROI) is -46.30% and its monthly performance is recorded as 0.60%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) quarterly revenue growth is 19.22%.